BSX
Boston Scientific
$44.33
▼ 2.1%Updated Today 7:15 PM ET
▼ Down 55.3% over the last 12 months
Market Cap
$67.32B
P/E
18.84x
Forward P/E (est.)
13.46x
ROE
14.9%
Revenue Growth
17.4%
EPS Growth
74.7%
Profit Margin
17.3%
FCF Yield
3.5%
Debt / Equity
0.47x
ROIC
9.0%
Interest Coverage
10.35x
Current Ratio
1.9x
Dividend Yield
—
Implied Growth (rev. DCF)
3.4%
Rating Score
71/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what BSX's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. BSX trades near $44.33, below its 50-day average ($54.92) and 200-day average ($81.20). Price below both averages is a downtrend — momentum is against buyers for now.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 29 it is oversold — selling has been heavy and a bounce is possible.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently negative — short-term momentum is fading.
Volatility — ATR. Average True Range is the typical daily move. BSX's is $1.45 (~3.3% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month BSX found buyers near $44.44 (support) and sellers near $58.51 (resistance); its 52-week range is $44.44–$109.50. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 1.3× the 20-day average — heavier than usual, which adds conviction to the move. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Boston Scientific (BSX) is a large-cap company in the Health Care Equipment industry, part of the Health Care sector of the S&P 500, with a market value around $67.32B.
In its latest reported year it generated about $20.07B in revenue.
Our model rates BSX Favorable (71/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
14.0%
Revenue moved from $11.89B in 2021 to $20.07B in 2025, a 14.0% compound annual growth rate. The most recent year grew a strong 17.4% year over year. Consistent top-line growth is one sign of healthy demand.
Gross Margin
69.0%
Operating Margin
18.0%
Net Margin
17.3%
ROE
14.9%
Boston Scientific keeps about 17.3% of each sales dollar as net profit, with a 69.0% gross margin and 18.0% operating margin. Return on equity is 14.9% and return on invested capital about 9.0%. Margins this wide usually signal pricing power or a cost advantage.
Total Debt
$4.81B
Net Debt
$3.35B
Net Debt / EBITDA
0.93x
Debt / Equity
0.47x
Leverage: debt-to-equity is 0.5x, and operating profit covers interest about 10.3x, with a current ratio of 1.9x. That is a conservative balance sheet — a cushion in downturns. It carries roughly $4.81B of total debt against $1.45B of cash.
Operating CF
$4.53B
Free Cash Flow
$3.66B
FCF Margin
18.2%
In the latest year Boston Scientific produced about $4.53B of operating cash flow and $3.66B of free cash flow after capital spending. That is a free-cash-flow yield of about 3.5% on today's price. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
18.84x
P/S
3.47x
P/B
5.63x
EV / EBITDA
14.67x
BSX trades at 18.8x trailing earnings (about 13.5x on estimated forward earnings), 3.5x sales, and 5.6x book value. Reverse-engineering today's price implies the market expects roughly 3.4% long-term free-cash-flow growth. That is a fairly typical valuation for a profitable company.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How BSX stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), BSX ranks #4 of 59 by our overall rating. It trades at a discount versus the sector on earnings (18.8x P/E vs. 25.4x median) with a similar return on equity (14.9% vs. 14.9%) and faster revenue growth (17.4% vs. 7.9%).
P/E vs sector
18.8x
median 25.4x
ROE vs sector
14.9%
median 14.9%
Growth vs sector
17.4%
median 7.9%
Sector rank
#4
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$55.37 – $95.64
vs. $44.33 today · expected CAGR 5% – 17%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $23.49B | $27.48B | $32.15B | $37.62B | $44.01B |
| Net income | $3.99B | $4.67B | $5.47B | $6.39B | $7.48B |
| EPS | $2.69 | $3.14 | $3.68 | $4.30 | $5.03 |
| Share price (low) | $29.55 | $34.57 | $40.45 | $47.33 | $55.37 |
| Share price (high) | $51.04 | $59.72 | $69.87 | $81.74 | $95.64 |
| CAGR (low–high) | -33% / 15% | -12% / 16% | -3% / 16% | 2% / 17% | 5% / 17% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for BSX:
- Revenue is growing 17.4% a year, a sign of real demand.
- High net margins (17.3%) point to pricing power or efficiency.
- A conservative balance sheet (debt/equity 0.5x) lowers risk.
- Our model's overall read is Favorable (71/100).
The case against BSX:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen favourably: Boston Scientific is a large-cap health care business still growing nicely, with solid profitability, and a sound balance sheet. It trades at 18.8x earnings, which our model scores Favorable (71/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.